文献速递肝病

综述:全球非酒精性脂肪性肝病的流行病学负担

Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world.
PubMed 文献 · Aliment Pharmacol Ther · 2022-07-26

该综述通过检索PubMed中关于非酒精性脂肪性肝病(NAFLD)的流行病学、患病率、发病率和合并症文献,汇总了全球疾病负担数据。2016年全球NAFLD患病率为25%,2019年升至超过30%;亚洲、拉丁美洲和中东-北非地区的患病率分别为30.8%、34.5%和42.6%。NAFLD总体死亡率约为每1000人年15-20例,在非酒精性脂肪性肝炎(NASH)患者中显著升高。

要点

  • 2016年全球NAFLD患病率为25%,2019年升至超过30%。
  • 亚洲、拉丁美洲和中东-北非地区患病率分别为30.8%、34.5%和42.6%。
  • 普通人群中NASH患病率估计为2%至6%,NAFLD患者中约7%有晚期纤维化。

核心结论

  • NAFLD是全球公共卫生问题,在亚洲、中东-北非和拉丁美洲疾病负担很高;需要研究以更好地量化NAFLD的全面影响并制定提高认识和风险分层的策略。

研究设计与样本

  • 综述:通过PubMed检索NAFLD、流行病学、患病率、发病率和合并症相关文献,共复习超过250篇文章。

主要发现

  • 2016年全球NAFLD患病率为25%,2019年升至超过30%。
  • 亚洲、拉丁美洲和中东-北非地区患病率分别为30.8%、34.5%和42.6%。
  • 患病率随年龄增长而增加;男性患病率较高,但绝经后女性患病率相似。
  • 瘦型NAFLD患病率为11.2%;普通人群中NASH患病率估计为2%至6%。
  • 约7%的NAFLD患者有晚期纤维化,NASH患者中晚期纤维化比例为21%至50%;NAFLD相关总体死亡率为每1000人年15-20例,NASH患者中尤其合并代谢综合征组分者死亡率显著增加;近期数据显示全球NAFLD死亡/患病率在增加,但患者和医疗提供者对NAFLD的认知仍然较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. AIM: To review the global epidemiology of NAFLD METHODS: We retrieved articles from PubMed using search terms of NAFLD, epidemiology, prevalence, incidence, and comorbidities. RESULTS: Over 250 articles were reviewed. In 2016, the global NAFLD prevalence was 25%; this increased to >30% in 2019. Prevalence in Asia, Latin America and Middle East-North Africa (MENA) was 30.8%, 34.5% and 42.6%, respectively. Prevalence increased with age. Although prevalence was higher in men, prevalence in post-menopausal women was similar. NAFLD prevalence was higher in certain subpopulations, especially among the obese and those with metabolic syndrome (MS). However, the prevalence of lean NAFLD was 11.2%. The global prevalence of non-alcoholic steatohepatitis (NASH) is estimated between 2% and 6% in the general population. Approximately 7% of patients with NAFLD have advanced fibrosis; rates were between 21% and 50% among patients with NASH. Overall mortality related to NAFLD was 15-20 per 1000 person-years, and increased substantially in patients with NASH, especially in those with components of MS. Recent data suggest mortality/morbidity from NAFLD is increasing globally but NAFLD awareness remains low among patients and healthcare providers. CONCLUSIONS: NAFLD poses a global public health problem with a very high disease burden in Asia, MENA and Latin America. Research is needed to better quantify the full impact of NAFLD and to develop strategies to improve awareness and risk stratification.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Henry L, Paik J, Younossi ZM, et al. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022. PMID: 35880713. doi:10.1111/apt.17158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。